Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma
English

I Dávila González, F Moreno Benítez, S Quirce
2019 Journal of investigational allergology & clinical immunology  
Eosinophilic asthma is the most common phenotype of severe asthma. It is characterized by abnormal production and release of type 2 cytokines from T helper type 2 (T H 2) lymphocytes and type 2 innate lymphoid cells, such as IL-5. This leads to a persistent increase and activation of eosinophils in blood and the airways despite treatment with high-dose inhaled corticosteroids. Eosinophil differentiation, survival, and activation are preferentially regulated by IL-5, a cytokine that binds to the
more » ... e that binds to the IL-5 receptor (IL-5R), which is located on the surface of eosinophils or basophils and plays a critical role in the pathogenesis and severity of asthma. Benralizumab is a monoclonal antibody that binds to IL-5R via its Fab domain, blocking the binding of IL-5 to its receptor and resulting in inhibition of eosinophil differentiation and maturation in bone marrow. In addition, this antibody is able to bind through its afucosylated Fc domain to the RIIIa region of the Fc receptor on NK cells, macrophages, and neutrophils, thus strongly inducing antibody-dependent, cell-mediated cytotoxicity in both circulating and tissue-resident eosinophils. This double function of benralizumab induces almost complete fast and maintained depletion of eosinophils that is much greater than that induced by other monoclonal antibodies targeting the IL-5 pathway, such as mepolizumab and reslizumab. This review focuses on benralizumab as an alternative to other agents targeting the IL-5 pathway in the treatment of eosinophilic asthma. receiving medium to high-dose ICSs plus a LABA with or without OCSs and additional asthma controllers. Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; OCS, oral corticosteroid. Dávila González I, et al.
doi:10.18176/jiaci.0385 fatcat:xluy7ytg3rdfxi4djlzrpvurwi